Hypertension

>

Latest News

Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension / image credit  ©Sundry Photos
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension

September 9th 2025

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds
Salt Substitute Use Remains Rare Among US Adults With Hypertension, Two-Decade Survey Finds

September 8th 2025

Fewer Than 1 in 4 Women Maintain Optimal CV Health in Menopause: Daily Dose / image credit: ©New Africa/AdobeStock
Fewer Than 1 in 4 Women Maintain Optimal CV Health in Menopause: Daily Dose

August 20th 2025

Guideline Topline: 2025 AHA/ACC Hypertension / image credit Dan Jones, MD, University of Mississippi Foundation
AHA/ACC Release Revised Hypertension Clinical Practice Guideline to Reduce CVD Risk

August 15th 2025

Cardiovascular Health
Only 1 in 5 Women Meet Heart Health Targets at Midlife, and These 4 Factors Matter Most

August 4th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.